GBR-13069
Glycogen Storage Disease Type I
Glycogen Storage Disease Type I (GSD I), also known as von Gierke disease, is a metabolic disorder characterized by the accumulation of glycogen in the liver and kidneys due to a deficiency in the enzyme glucose-6-phosphatase. This enzyme is crucial for the final step of gluconeogenesis and glycogenolysis, which is the conversion of glucose-6-phosphate into free glucose.
Pathophysiology
GSD I is caused by mutations in the G6PC gene, which encodes the glucose-6-phosphatase enzyme. The deficiency of this enzyme leads to the inability to convert glucose-6-phosphate into glucose, resulting in the accumulation of glycogen and fat in the liver and kidneys. This accumulation causes hepatomegaly and nephromegaly, and the inability to maintain normal blood glucose levels leads to hypoglycemia.
Clinical Features
Patients with GSD I typically present in infancy with symptoms such as severe hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. The hypoglycemia can lead to seizures and developmental delay if not managed properly. Other features include a "doll-like" facial appearance, short stature, and delayed puberty.
Diagnosis
The diagnosis of GSD I is based on clinical presentation, biochemical tests, and genetic testing. Biochemical tests reveal hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia. Genetic testing can confirm mutations in the G6PC gene.
Management
Management of GSD I focuses on maintaining normal blood glucose levels to prevent hypoglycemia. This is achieved through frequent feedings of cornstarch and a high-carbohydrate diet. In some cases, allopurinol is used to manage hyperuricemia, and lipid-lowering agents may be used to control hyperlipidemia.
Prognosis
With proper management, individuals with GSD I can lead relatively normal lives, although they may have an increased risk of developing hepatic adenomas and renal disease later in life.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD